<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14855">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913482</url>
  </required_header>
  <id_info>
    <org_study_id>BP39056</org_study_id>
    <secondary_id>2016-000778-40</secondary_id>
    <nct_id>NCT02913482</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Infants With Type1 Spinal Muscular Atrophy (Firefish)</brief_title>
  <official_title>A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Infants With Type 1 Spinal Muscular Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, multi-center clinical study is to assess the safety, tolerability,
      pharmacokinetic, pharmacodynamics, and efficacy of RO7034067 in infants with Type 1 spinal
      muscular atrophy (SMA). The study consists of two parts, an exploratory dose finding part
      (Part 1) and a confirmatory part (Part 2) which will investigate RO7034067 for 24-months at
      the dose selected in Part 1.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2016</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Part 2 Dose of RO7034067</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III)</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 25 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum plasma concentration (Cmax) of RO7034067</measure>
    <time_frame>Pre-dose (PrD) (Hour 0) and 2, 4, 6, hour post-dose (PoD) on Days 1, 28, 84, 364, 546, 728; PrD on Day 2; PrD and 4 hours PoD on Days 7, 14, 56, 119, 182, 245, 301, 427, 490, 609, 672</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Maximum plasma concentration (Cmax) of RO7034067</measure>
    <time_frame>2, 4, 6, hours PoD on Day 1; PrD (Hour 0) on Days 2, 14, 119, 245, 364, 427, 490, 609, 728; PrD and 2, 4, 6 hours PoD on Days 28, 56, 182, 301, 546, 672</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area under the curve (AUC) of RO7034067</measure>
    <time_frame>PrD (Hour 0) and 2, 4, 6, hour PoD on Days 1, 28, 84, 364, 546, 728; PrD on Day 2; PrD and 4 hours PoD on Days 7, 14, 56, 119, 182, 245, 301, 427, 490, 609, 672</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Area under the curve (AUC) of RO7034067</measure>
    <time_frame>2, 4, 6, hours PoD on Day 1; PrD (Hour 0) on Days 2, 14, 119, 245, 364, 427, 490, 609, 728; PrD and 2, 4, 6 hours PoD on Days 28, 56, 182, 301, 546, 672</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Concentration at the end of a dosing interval (Ctrough) of RO7034067</measure>
    <time_frame>PrD (Hour 0) Days 1, 2, 7, 14, 28, 56, 84, 119, 364, 546</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Concentration at the end of a dosing interval (Ctrough) of RO7034067</measure>
    <time_frame>PrD (Hour 0) on Days 2, 14, 28, 56, 119, 182, 301, 546, 672</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death</measure>
    <time_frame>Baseline up to 25 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Permanent Ventilation</measure>
    <time_frame>Baseline up to 25 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival of Motor Neuron (SMN) Protein Levels in Blood</measure>
    <time_frame>pre-dose on Day 1, 14, 28, 119, 245, 364, 609, 728</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood</measure>
    <time_frame>Day 1, 14, 28, 245, 364, 609, 728</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24</measure>
    <time_frame>Baseline, Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24</measure>
    <time_frame>Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale</measure>
    <time_frame>Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants who Achieve a Reduction of 30 Degrees in Their Phase Angle From Baseline, as Measured by Respiratory Inductance Plethysmography at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants who Achieve an Increase of at Least 0.3 millivolt From Baseline in Their Compound Muscle Action Potential Negative Peak Amplitude at Month 12 and 24</measure>
    <time_frame>Baseline, Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death or Permanent Ventilation, Whichever Occurred First</measure>
    <time_frame>Baseline up to 25 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24</measure>
    <time_frame>Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants who are Sitting Without Support at 24-months</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants who are Stands Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants who are Walks Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Muscular Atrophy, Spinal</condition>
  <arm_group>
    <arm_group_label>Part 1 (Exploratory dose finding): RO7034067</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple ascending doses of RO7034067, administered orally once daily for 4 weeks followed by open-label extension phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Confirmatory): RO7034067</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7034067, administered orally at the maximum tolerated dose defined in part 1 of the study. Treatments will continue maximum up to 24-months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7034067</intervention_name>
    <description>RO7034067 will be administered orally.</description>
    <arm_group_label>Part 1 (Exploratory dose finding): RO7034067</arm_group_label>
    <arm_group_label>Part 2 (Confirmatory): RO7034067</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical history, signs or symptoms attributable to Type 1 SMA with onset after 28
             days but prior to the age of 3 months

          -  Gestational age of 37 to 42 weeks

          -  Confirmed diagnosis of 5q-autosomal recessive SMA

          -  Participants has two survival motor neuron 2 (SMN2) gene copies, as confirmed by
             central testing

          -  Body weight greater than or equal to (&gt;=) third percentile for age, using appropriate
             country-specific guidelines

          -  Receiving adequate nutrition and hydration (with or without gastrostomy) at the time
             of screening, in the opinion of the Investigator

          -  Adequately recovered from any acute illness at the time of screening and considered
             well-enough to participate in the opinion of the Investigator

        Exclusion Criteria:

          -  Concomitant or previous participation in any investigational drug or device study
             within 90 days prior to screening or 5 half-lives, whichever is longer

          -  Concomitant or previous participation in a SMN2 targeting antisense oligonucleotide
             or SMN2 splicing modifier or gene therapy study

          -  Any history of cell therapy

          -  Hospitalization for pulmonary event within the last 2 months, or planned at the time
             of screening

          -  Presence of clinically relevant electrocardiogram (ECG) abnormalities before study
             drug administration

          -  Unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system
             diseases

          -  Participants requiring invasive ventilation or tracheostomy

          -  Participants requiring awake non-invasive ventilation or with awake hypoxemia
             (arterial oxygen saturation less than [&lt;] 95 percent [%]) with or without ventilator
             support

          -  Participants with a history of respiratory failure or severe pneumonia, and have not
             fully recovered their pulmonary function at the time of screening

          -  Multiple or fixed contractures and/or hip subluxation or dislocation at birth

          -  Presence of non-SMA related concurrent syndromes or diseases

          -  Any major illness within one month before the screening examination or any febrile
             illness within one week prior to screening and up to first dose administration

          -  Any inhibitor of cytochrome P450 (CYP) 3A4 and/or any Organic Cation Transporter 2
             (OCT-2) and multidrug and toxin extrusion (MATE) substrates taken within 2 weeks
             and/or any inducer of CYP3A4 taken within 4 weeks (or within 5-times the elimination
             half-life, whichever is longer) prior to dosing or participants (and the mother, if
             breastfeeding the infant) taking any nutrients known to modulate CYP3A activity and
             any known flavin containing monooxygenase (FMO) 1 or FMO3 inhibitors or substrates

          -  Prior use, anticipated need for hydroxychloroquine, vigabatrin, retigabine, or any
             other drug known to cause retinal toxicity during the study

          -  Recent history (less than 6 months) of ophthalmic disease that would interfere with
             the conduct of the study as assessed by an ophthalmologist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>7 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP39056 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Clin Rsch Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science Uni</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center - Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Utah Clinical Neurosciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chr de La Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique - L'ESCALE</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier, Hopital Gui de Chauliac; Service de Neuropediatrie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg; Klinik für Neuropädiatrie und Muskelerkrankungen</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Neurologico &quot;Carlo Besta&quot;; UO di Neurologia dello Sviluppo</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderspitalbeider Basel_Abteilung für Neuro- und Entwicklungspädiatrie</name>
      <address>
        <city>Basel</city>
        <zip>4005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Hospital; Pediatric Neurology</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe University, School of Medicine; Pediatrics Department; Pediatrics Child Neurology Unit</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>September 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
